arrow
J

Jason T. Romancik

hackensack university medical center
H指数:12
被引数:680

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

CD19 CAR T细胞疗法在原发性皮肤弥漫大B细胞淋巴瘤,腿型中的应用

2026-01-300
OAAI
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium

CAR-T作为二线、三线、四线或更后期治疗在侵袭性B细胞淋巴瘤中的疗效:ABC联盟的真实世界证据

2025-11-100
OAAI
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium

大B细胞淋巴瘤在CAR T细胞治疗失败后使用双特异性抗体的疗效——ABC Consortium研究的结果

2025-10-240
OAAI
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments

自体移植或CAR-T作为MYC重排大B细胞淋巴瘤患者在挽救治疗后缓解期的巩固治疗选择

2025-04-150
PRE
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
2024-11-141
OAAI
A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL)

一项关于使用ACE1831(由异基因γδT细胞与抗CD-20抗体偶联组成)治疗B细胞复发/难治性非霍奇金淋巴瘤(R/R NHL)患者的Ⅰ期、开放标签、多中心研究。

BLOOD
IF23.1
2024-11-050
PRE
Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

CAR T细胞疗法治疗转化型滤泡性淋巴瘤的临床结局:一项美国多中心真实世界分析

BLOOD
IF23.1
2024-11-050
PRE
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
2024-05-285
OAAI
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
2024-05-166
OAAI
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

CAR T细胞治疗后继发性中枢神经系统淋巴瘤患者的结局: 一项多中心队列研究

2023-11-0911
OAAI
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
2023-08-1120
OAAI
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
2023-06-287
OAAI
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL

所有car-t患者和侵袭性b-nhl的car-t后失败的围术期实践模式和生存预测指标

2023-06-1427
OAAI
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
2021-03-1232
OA